Company Description
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States.
The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S.
epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S.
epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease.
It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations.
Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jun 16, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Francisco Salva |
Contact Details
Address: 21 Business Park Drive Branford, Connecticut 06405 United States | |
| Phone | 203 646 6446 |
| Website | azitrainc.com |
Stock Details
| Ticker Symbol | AZTR |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 1701478 |
| CUSIP Number | 05479L203 |
| ISIN Number | US05479L3024 |
| Employer ID | 46-4478536 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Francisco D. Salva | President, Chief Executive Officer and Director |
| Dr. Travis M. Whitfill M.P.H., Ph.D. | Co-Founder, Chief Operating Officer, Secretary and Director |
| Norman Staskey | Chief Financial Officer and Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 23, 2026 | 8-K | Current Report |
| Mar 13, 2026 | 8-K | Current Report |
| Mar 5, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 5, 2026 | 8-K | Current Report |
| Feb 27, 2026 | 8-K | Current Report |
| Feb 27, 2026 | 10-K | Annual Report |
| Feb 6, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Feb 6, 2026 | 8-K | Current Report |
| Jan 30, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 2, 2026 | DEF 14A | Other definitive proxy statements |